BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24924123)

  • 1. A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population.
    Hannibal CG; Vang R; Junge J; Frederiksen K; Kjaerbye-Thygesen A; Andersen KK; Tabor A; Kurman RJ; Kjaer SK
    Gynecol Oncol; 2014 Aug; 134(2):267-73. PubMed ID: 24924123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.
    Hannibal CG; Vang R; Junge J; Frederiksen K; Kurman RJ; Kjaer SK
    Gynecol Oncol; 2017 Jan; 144(1):174-180. PubMed ID: 27836204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
    Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
    Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
    Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
    Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006.
    Hannibal CG; Vang R; Junge J; Kjaerbye-Thygesen A; Kurman RJ; Kjaer SK
    Gynecol Oncol; 2012 Jun; 125(3):655-60. PubMed ID: 22370600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion.
    Prat J; De Nictolis M
    Am J Surg Pathol; 2002 Sep; 26(9):1111-28. PubMed ID: 12218568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-grade Serous Carcinoma of the Ovary: Clinicopathologic Analysis of 52 Invasive Cases and Identification of a Possible Noninvasive Intermediate Lesion.
    Ahn G; Folkins AK; McKenney JK; Longacre TA
    Am J Surg Pathol; 2016 Sep; 40(9):1165-76. PubMed ID: 27487741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases.
    Seidman JD; Kurman RJ
    Am J Surg Pathol; 1996 Nov; 20(11):1331-45. PubMed ID: 8898837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
    Xing D; Suryo Rahmanto Y; Zeppernick F; Hannibal CG; Kjaer SK; Vang R; Shih IM; Wang TL
    Hum Pathol; 2017 Oct; 68():87-91. PubMed ID: 28873354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian Low-grade Serous Carcinoma: A Clinicopathologic Study of 33 Cases With Primary Surgery Performed at a Single Institution.
    Okoye E; Euscher ED; Malpica A
    Am J Surg Pathol; 2016 May; 40(5):627-35. PubMed ID: 26900814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.
    Ardighieri L; Zeppernick F; Hannibal CG; Vang R; Cope L; Junge J; Kjaer SK; Kurman RJ; Shih IeM
    J Pathol; 2014 Jan; 232(1):16-22. PubMed ID: 24307542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators.
    Seidman JD; Kurman RJ
    Hum Pathol; 2000 May; 31(5):539-57. PubMed ID: 10836293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study.
    Rasmussen ELK; Hannibal CG; Dehlendorff C; Baandrup L; Junge J; Vang R; Kurman RJ; Kjaer SK
    Gynecol Oncol; 2017 Mar; 144(3):571-576. PubMed ID: 28108026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
    Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N
    Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal Proliferations in Completely Examined Fallopian Tubes Accompanying Ovarian Low-grade Serous Tumors: Neoplastic Precursor Lesions or Normal Variants of Benign Mucosa?
    Wolsky RJ; Price MA; Zaloudek CJ; Rabban JT
    Int J Gynecol Pathol; 2018 May; 37(3):262-274. PubMed ID: 28700429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis.
    Kurman RJ; Vang R; Junge J; Hannibal CG; Kjaer SK; Shih IeM
    Am J Surg Pathol; 2011 Nov; 35(11):1605-14. PubMed ID: 21997682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral Heterogeneity Accounts for Apparent Progression of Noninvasive Serous Tumors to Invasive Low-grade Serous Carcinoma: A Study of 30 Low-grade Serous Tumors of the Ovary in 18 Patients With Peritoneal Carcinomatosis.
    Seidman JD; Savage J; Krishnan J; Vang R; Kurman RJ
    Int J Gynecol Pathol; 2020 Jan; 39(1):43-54. PubMed ID: 30480646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late recurrence of pStage 1 low-grade serous ovarian tumor presenting as a symptomatic bone metastasis: a case report.
    Kubo C; Nagata S; Fukuda T; Kano R; Tanaka T; Nakanishi K; Ohsawa M; Nakatsuka SI
    Diagn Pathol; 2018 Jun; 13(1):43. PubMed ID: 29960592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimplants in serous borderline tumors of the ovary: a clinicopathologic study of 30 cases of a process to be distinguished from serous adenocarcinoma.
    Rollins SE; Young RH; Bell DA
    Am J Surg Pathol; 2006 Apr; 30(4):457-62. PubMed ID: 16625091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.